Login to Your Account



Avonex(t): FDA gives nod to Plegridy for MS, oral Tecfidera still Biogen mouth that roared

By Randy Osborne
Staff Writer

Monday, August 18, 2014

Biogen Idec Inc. is keeping its injectable bases covered in relapsing multiple sclerosis with the approval Friday of Plegridy, given by an auto-injector pen or prefilled syringe every two weeks, a significant half-life advantage over the firm's Avonex for RMS, given weekly.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription